Skip to main content
. 2020 Mar 6;10:4211. doi: 10.1038/s41598-020-60156-6

Figure 3.

Figure 3

Combined AZD2014 and dasatinib treatment significantly inhibits tumor growth in a mouse allograft schwannoma model. (A) Immunoblotting of in vivo mouse schwannomas from 2 independent Nf2−/− Schwann cell (SC)-implanted tumors show activated mTORC1 (pS6) and mTORC2 (pAktS473, SGK1, pNDRG1) signatures. (B) Immunoblotting of mouse allograft schwannomas also show activated pEPHA2 and robustly activated pSrc/SFK. (C) Tumor growth delay, defined by the time required for tumors to reach 1 cm in diameter. Vehicle-treated mice (n = 13); mice treated with AZD2014 alone (15 mg/kg, n = 16); mice treated with dasatinib alone (15 mg/kg, n = 16); and mice treated with a combination of AZD2014 and dasatinib (n = 14). Representative data from two independent experiments; mean ± SEM. (D) Immunoblot of in vivo mouse schwannomas from different treatment groups confirmed that targets of AZD2014 and dasatinib were inhibited. Immunoblot quantitation, performed using ImageJ/Fiji, is shown above the blots.